Edgewise Therapeutics (NASDAQ:EWTX – Free Report) had its price target hoisted by stock analysts at JPMorgan Chase & Co. from $24.00 to $25.00 in a research report issued to clients and investors on Friday, The Fly reports. JPMorgan Chase & Co.‘s price target suggests a potential upside of 222.58% from the company’s current price. Separately, […]
Opaleye Management Inc. reduced its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) by 3.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 611,400 shares of the company’s stock after selling 23,600 shares during the period. Edgewise Therapeutics comprises approximately 1.9% of Opaleye Management Inc.’s holdings, […]
Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,430,000 shares, an increase of 6.2% from the April 15th total of 4,170,000 shares. Based on an average daily volume of 173,000 shares, the short-interest ratio is […]
Truist Financial started coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX – Get Rating) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating on the stock. Edgewise Therapeutics Price Performance Shares of NASDAQ EWTX opened at $9.53 on Monday. Edgewise Therapeutics has a 1 year low of $5.41 and […]
Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) CEO Kevin Koch sold 3,203 shares of the firm’s stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $8.90, for a total transaction of $28,506.70. Following the sale, the chief executive officer now owns 7,213 shares in the company, valued […]